{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:26:23Z","timestamp":1761845183551,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jacl.2020.04.007","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T02:38:50Z","timestamp":1587782330000},"page":"425-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Temporal decline in non\u2013high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Gloria Lena","family":"Vega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jijia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M.","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jacl.2020.04.007_bib1","first-page":"S75","article-title":"9. Cardiovascular disease and risk management","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2020.04.007_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.04.007_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid-Lowering Arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2020.04.007_bib4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2020.04.007_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2020.04.007_bib6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/jcem.86.3.7304","article-title":"Clinical review 124: diabetic dyslipidemia: causes and consequences","volume":"86","author":"Goldberg","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2020.04.007_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.04.007_bib9","series-title":"proceedings of the thirty-first annual SAS\u00ae Users Group international conference","first-page":"26","article-title":"The big four: analyzing complex sample survey data using SAS, SPSS, STATA, and SUDAAN","author":"Siller","year":"2006"},{"key":"10.1016\/j.jacl.2020.04.007_bib10","series-title":"SAS Global Forum. 246","article-title":"Getting the most out of the SAS survey procedures: repeated replication methods, subpopulation analysis, and missing data options in SAS v9. 2 Paper 246-2009","author":"Berglund","year":"2009"},{"issue":"8","key":"10.1016\/j.jacl.2020.04.007_bib11","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.2337\/diacare.28.8.1916","article-title":"Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes","volume":"28","author":"Liu","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jacl.2020.04.007_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jacl.2020.04.007_bib13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacl.2020.04.007_bib14","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2020.04.007_bib15","first-page":"S1","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2020.04.007_bib16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jacl.2020.04.007_bib17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2009-1952","article-title":"Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin","volume":"95","author":"Lakoski","year":"2010","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:35:52Z","timestamp":1761831352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287420300775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1933287420300775"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2020.04.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal decline in non\u2013high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2020.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}